To investigate the molecular mechanisms underlying resistance against the FGFR inhibitor nintedanib, we selected one FGFR1-driven SCLC (DMS114) and two NSCLC cell lines (NCI-H1703, NCI-H520) for acquired nintedanib resistance. This evidence concerns the gene FGFR1 and small cell lung carcinoma.